Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...

We recently compiled a list of the Jim Cramer’s Game Plan: 17 Stocks in Focus. In this article, we are going to take a look ...

Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...

Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting earnings tomorrow afternoon. Here’s what investors should ...

PCE inflation data, Fed speakers, more earnings will be in focus this week. • Nvidia’s robust performance in the burgeoning AI space and strong guidance position it as a clear buy. • Lowe’s’ struggles ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Halozyme (HALO – Research Report), Walgreens Boots Alliance ...

Here is how the Barron’s Roundtable members’ picks performed. Find investment ideas for your portfolio with the latest stock picks from Barron’s below. These picks are the product of the ...

Palantir stock fell more than 10% Wednesday following a report the Trump administration is planning deep cuts to the defense budget. The "DOGE" efficiency commission has begun posting details of the ...